{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-025238","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.868354+00:00","generated_at":"2026-05-26T06:08:51.109550+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tivic Health names Michael Handley COO and President of Tivic Biopharma following Statera license","bullets":["Handley appointed COO and President of new Tivic Biopharma division, effective Feb 18, 2025.","Compensation: $300k base salary, up to 35% bonus, 600k RSUs vesting over 4 years.","Handley previously CEO of Statera Biopharma; helped commercialize 17 drugs/devices worth ~$7B in sales.","Role includes advancing late-stage Entolimod (TLR5 agonist) for radiation protection and immune indications.","Appointment follows Feb 11 exclusive license of Entolimod from Statera, previously disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-025238","json":"https://secwatch.observer/filing/0000950170-25-025238.json","markdown":"https://secwatch.observer/filing/0000950170-25-025238.md","text":"https://secwatch.observer/filing/0000950170-25-025238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/0000950170-25-025238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/tivc-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:08:51.109550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6441313fb0","claim":"Michael Handley was appointed as Chief Operating Officer and President of Tivic Biopharma division at Valion Bio, Inc..","evidence_excerpt":"On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/0000950170-25-025238-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer and President of Tivic Biopharma division"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}